Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...